News and press announcements

New Chairman of the Main Board of ARPharM was Elected

08/07/2022, Sofia

At a regular meeting of the General Assembly of the Association of the Research-based Pharmaceutical Manufacturers in Bulgaria (ARPharM), held on May 19, 2022, two new members of the Association's Management Board (MB) were elected.

Dr. Stamen Bankovski, director for Bulgaria, Romania, and Hungary of the pharmaceutical company Astellas, was elected Chairman of the ARPharM Main Board.

The other new member of the Main Board is Dr. Boryana Alexieva - Head of Relations with Governmental Structures, Institutions and Patient Organizations in Janssen - the pharmaceutical companies of Johnson & Johnson, Bulgaria.

The new figures in the management of ARPharM will continue the organisation's efforts in the direction of improving Bulgarian patients' access to quality, modern and effective medical treatment and will cooperate with all state institutions and patient organisations for the preparation of balanced policies to improve the healthcare system in our country.

read more
A New Main Board of The Association Of Research-Based Pharmaceutical Manufacturers in Bulgaria Is Elected

May 31, 2021, Sofia

Dr. Svetoslav Tsenov is the New Chairperson of the Managing Board of ARPharM

The regular annual General Assembly of the Association of Research-based Pharmaceutical Manufacturers in Bulgaria (ARPharM), held on the 18th of May 2021 elected a new Managing Board of the Association.

Dr. Svetoslav Tsenov, Director and Head of Strategic Development for Bulgaria, Central and Eastern Europe, Greece, Portugal and the Baltic Region of the pharmaceutical company Astellas was elected Chairman of the Management Board of ARPharM for a two-years term. Dr. Krassimira Chemishanska, Executive Director of Amgen Bulgaria and Chairperson of the Association in the previous term, following a tradition of continuity, was elected a Vice-chairperson of the association.

read more
Interaction between pharmaceutical companies and medical professionals in COVID situation

May 12, 2020, Sofia

The Association of the Research-based Pharmaceutical Manufacturers (ARPharM) and its member companies are committed to the global fight against the COVID-19 pandemic due to coronavirus. Our thoughts are with the people affected by the infection and their loved ones, as well as with the doctors and pharmacists who are at the forefront in the fight to overcome the pandemic.

The Research-based pharmaceutical industry is focused on three key areas: • the development of new vaccines, diagnostics and drug therapies to combat COVID-19 - around 7 vaccine applicants and over 30 antiviral drugs at various stages of development or use are currently being investigated by innovative pharmaceutical companies in over 25 clinical trials to determine whether they are effective in preventing or treating patients with COVID-19 -;

read more


#WeWontRest Until We Make the Impossible Possible

For some impossible means it can’t be done, stop trying, give up now! For us - Impossible inspires us - to give everything, to try harder. To use science to change people’s lives for the better.

With mRNA technology, we’re making a new generation of vaccines; thanks to remyelinating therapies - rebuilding damaged nerves; by developing ground-breaking gene therapies - treating rare diseases.

With over 8,000 new medicines and vaccines in development, #WeWontRest until we make the impossible possible!

read more

#WeWontRest until there is a COVID-19 vaccine for everyone

Vaccines represent our best hope of moving out from under the shadow of the COVID-19 pandemic. Our members are working around the clock to develop a safe and effective COVID-19 vaccine.

read more

#WeWontRest in the fight against COVID-19

As the impact of COVID-19 continues to be felt across the world, the biopharmaceutical industry in Europe remains committed to global efforts to care for those affected, contain the outbreak and develop resources to tackle future outbreaks.

ARPharM member companies are working around the clock to find vaccines, diagnostics and treatments and ensure patients get access to the medicines they need.

Worldwide, there are more than 100 vaccine candidates in development and over 600 clinical trials underway to find a treatment to use in the fight against COVID-19.

read more

Members of the Association